AB Science S.A. (EPA:AB)

Market Cap	100.42M
Revenue (ttm)	1.07M
Net Income (ttm)	-7.83M
Shares Out	67.49M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	459,122
Average Volume	427,544
Open	1.592
Previous Close	1.496
Day's Range	1.476 - 1.598
52-Week Range	0.770 - 2.340
Beta	1.60
RSI	59.67
Earnings Date	Sep 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 39
• Stock Exchange: Euronext Paris
• Ticker Symbol: AB

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.